FemPulse Receives FDA IDE Approval for the Pivotal Clinical Trial of its Wearable Bioelectronic Device for Overactive Bladder in Women
December 11, 2024 15:18 ET
|
FemPulse
SAN FRANCISO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II...
FemPulse Announces Issuance of Patents in China and Australia
January 06, 2020 09:00 ET
|
FemPulse
MINNEAPOLIS, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Secures Equity Financing to Finalize Development of Proprietary Bioelectronic Device for Treatment of Overactive Bladder in Women
December 05, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Announces Enrollment of First Participant in Clinical Study for Personalized Treatment of Overactive Bladder (OAB) in Women
July 15, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, July 15, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse to Participate in Panel Discussion at the 2019 Bioelectronic Medicine Forum
March 26, 2019 09:01 ET
|
FemPulse
MINNEAPOLIS, March 26, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Appoints Dr. Robert Kieval as Chief Scientific and Clinical Officer
March 05, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, March 05, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Announces Enrollment in Multi-Center EVANESCE-OAB Study
February 25, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, Feb. 25, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...